Overview

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Status:
Completed

Trial end date:
2021-08-12

Target enrollment:

Participant gender:

Summary

This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion

Phase:

Phase 3

Details

Lead Sponsor:

Repurposed Therapeutics, Inc.

Collaborator:

Defender Pharmaceuticals, Inc.

Treatments:

Scopolamine